Silence Therapeutics Plc (SLN) Stock Price & Analysis
Silence Therapeutics Plc (SLN) fell 1.02% to USD 13.55 as of September 9, 2026 at 22:07 UTC, according to Nexqual real-time market data.
SLN last closed at USD 13.69; the session ranged USD 13.36–14 on volume of 645,879 shares. Market capitalization is $842.19M, with a 52-week range of USD 4.19–17.58 (NGM). Source: Nexqual, September 9, 2026 at 22:07 UTC.
Key Statistics (as of September 9, 2026 at 22:07 UTC)
| Price | USD 13.55 |
|---|---|
| Change | ▼ 1.02% (down) |
| Previous Close | USD 13.69 |
| Open | USD 13.6 |
| Day Range | USD 13.36 – 14 |
| 52-Week Range | USD 4.19 – 17.58 |
| Volume | 645,879 shares |
| Market Cap | $842.19M |
| Exchange | NGM |
Technical Analysis (SLN)
Nexqual's technical model rates SLN "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of September 9, 2026 at 22:07 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.88 (neutral) |
| vs SMA50 | Above (USD 12.18) |
| MACD | 0.57 (positive) |
Analyst Ratings (SLN)
Wall Street analysts rate SLN "Buy" based on 6 analysts, with a mean price target of USD 33 (range USD 10–75), per Nexqual as of September 9, 2026 at 22:07 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 33 |
| High Target | USD 75 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 6 / 0 / 1 |
Earnings (SLN)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.18 |
| Revenue Estimate | $20,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.27 vs est -0.11 ▼ miss |
| 2026-03-31 | USD -0.33 vs est -0.09 ▼ miss |
| 2025-12-31 | USD -0.27 vs est -0.49 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.21 ▲ beat |
Source: Nexqual, September 9, 2026 at 22:07 UTC.
Financials & Fundamentals (SLN)
| Total Revenue | $615,000 |
|---|---|
| Gross Margin | +85.85% |
| Operating Margin | -10475.61% |
| Profit Margin | +0.00% |
| ROE | -90.41% |
| Debt / Equity | 0.29 |
| Current Ratio | 7.42 |
| Total Cash | $72.05M |
| Total Debt | $112,000 |
| Free Cash Flow | $-23.57M |
Source: Nexqual, September 9, 2026 at 22:07 UTC.
Financial Health Score (SLN)
Nexqual rates Silence Therapeutics Plc's overall financial health "Weak" across five dimensions, as of September 9, 2026 at 22:07 UTC.
| Growth | Critical — Revenue -99% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $72M cash, no debt |
| Cash Flow | Weak — FCF negative: -$24M, burning cash |
| Efficiency | Critical — ROE -90%, ROA -29.6% |
Ownership (SLN)
| Insider Ownership | +7.97% |
|---|---|
| Institutional Ownership | +39.68% |
| Shares Outstanding | 62.15M |
| Float | 37.84M |
| Short % of Float | +4.81% |
Source: Nexqual, September 9, 2026 at 22:07 UTC.
Leadership (SLN)
Silence Therapeutics Plc is led by Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D (age 71), Interim CEO & Chairman of the Board, per Nexqual as of September 9, 2026 at 22:07 UTC.
| Interim CEO & Chairman of the Board | Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D (age 71) |
|---|---|
| Executive VP, CFO, Secretary & Executive Director | Rhonda L. Hellums (age 54) |
| Chief Scientific Officer | Marie Wikstrom Lindholm |
Major Backers & Investors (SLN)
Notable institutional backers of Silence Therapeutics Plc include Siren, L.L.C., TCG Crossover Management, LLC, Redmile Group, LLC, according to Nexqual as of September 9, 2026 at 22:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Siren, L.L.C. | 5.5% |
| TCG Crossover Management, LLC | 5.04% |
| Redmile Group, LLC | 3.6% |
| Nantahala Capital Management, LLC | 2.24% |
| Citadel | 2.21% |
| Nextech Invest, Ltd. | 1.58% |
| Millennium Management | 1.51% |
| Ikarian Capital, LLC | 1.38% |
Source: Nexqual, September 9, 2026 at 22:07 UTC.
From Silence Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
- The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
- It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHVS | Pharvaris N.V. | USD 37.74 | ▲ 7.06% |
| BCYC | Bicycle Therapeutics plc | USD 4.01 | ▼ 6.86% |
| INBX | Inhibrx Biosciences, Inc. | USD 112.86 | ▼ 6.86% |
| KROS | Keros Therapeutics, Inc. | USD 11.31 | ▼ 0.09% |
| CGEM | Cullinan Therapeutics, Inc. | USD 21.31 | ▼ 3.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 22:07 UTC. This page is informational and not investment advice.